| Filed On | Filing |
|---|---|
| 08 May 2023 |
8-K/A: Submission of Matters to a Vote of Security Holders
In accordance with the voting results from our annual meeting of stockholders held on April 27, 2023, at which our board of directors recommended that stockholders vote for the option of every “1 Year” as the preferred frequency for futu... |
| 09 Aug 2011 |
8-K/A: Submission of Matters to a Vote of Security Holders
In accordance with the voting results from our annual meeting of stockholders held on April 28, 2011, at which our board of directors recommended that stockholders vote for the option of every “1 Year” as the preferred frequency for futu... |
| 16 Mar 2011 |
8-K/A: Financial Statements and Exhibits
On July 30, 2010, Lexicon Pharmaceuticals, Inc. (“Lexicon”) entered into an amended and restated purchase option agreement (the “Amended and Restated Purchase Option Agreement”) with Symphony Icon Holdings LLC (“Holdings”) and Symphony I... |
| 02 Sep 2009 |
8-K/A: Entry into a Material Definitive Agreement
This letter agreement (“Letter Agreement”) relates to the Second Amended and Restated Collaboration and License Agreement between Genentech, Inc. and Lexicon Pharmaceuticals, Inc. effective as of November 30, 2005 (“Agreement”). All capi... |
| 01 May 2008 |
8-K/A: Departure/Election of Directors or Officers; Compensation
We invite you to serve as a consultant to Lexicon Pharmaceuticals, Inc. (which, together with its subsidiaries and affiliates, is referred to as the “Company” or “Lexicon”). The purpose of this letter agreement (this “Agreement”) is to s... |
| 01 Nov 2005 |
8-K/A: Results of Operations and Financial Condition
THE WOODLANDS, TEXAS, NOVEMBER 1, 2005 -- Lexicon Genetics Incorporated (Nasdaq: LEXG), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today reported financial results for the... |
Loading...